Prab: CSV import

2025-04-08T18:03:42Z

CSV import

← Older revision		Revision as of 18:03, 8 April 2025
Line 1:		Line 1:
	[[File:Carnitine_structure.png\|Carnitine structure\|~~thumb~~]] '''Systemic Primary Carnitine Deficiency''' (SPCD), also known as '''Carnitine Uptake Defect''' or '''Carnitine Transporter Deficiency''', is a rare [[genetic disorder]] that affects the body's ability to transport [[carnitine]], a substance essential for the oxidation of long-chain [[fatty acids]]. This condition leads to a variety of symptoms, primarily affecting the [[muscle]]s and [[heart]], and can result in serious complications if not treated promptly.		{{SI}}
			{{Infobox medical condition
			\| name = Systemic primary carnitine deficiency
			\| image = [[File:Carnitine_structure.png\|left\|thumb\|Carnitine structure]]
			\| caption = Structure of carnitine
			\| synonyms = Primary carnitine deficiency, Carnitine uptake defect
			\| pronounce =
			\| specialty = [[Genetics]], [[Metabolism]]
			\| symptoms = [[Hypoglycemia]], [[Cardiomyopathy]], [[Muscle weakness]], [[Fatigue]]
			\| onset = [[Infancy]] or [[early childhood]]
			\| duration = [[Chronic]]
			\| causes = [[Genetic mutation]] in the [[SLC22A5]] gene
			\| risks =
			\| diagnosis = [[Blood test]], [[Genetic testing]]
			\| differential = [[Secondary carnitine deficiency]], [[Fatty acid oxidation disorders]]
			\| prevention =
			\| treatment = [[Carnitine supplementation]]
			\| medication =
			\| prognosis = Good with treatment
			\| frequency = 1 in 40,000 to 1 in 120,000
			\| deaths = Rare with treatment
			}}
			'''Systemic Primary Carnitine Deficiency''' (SPCD), also known as '''Carnitine Uptake Defect''' or '''Carnitine Transporter Deficiency''', is a rare [[genetic disorder]] that affects the body's ability to transport [[carnitine]], a substance essential for the oxidation of long-chain [[fatty acids]]. This condition leads to a variety of symptoms, primarily affecting the [[muscle]]s and [[heart]], and can result in serious complications if not treated promptly.
	==Causes==		==Causes==
	SPCD is caused by mutations in the [[SLC22A5]] gene, which encodes the organic cation transporter type 2 (OCTN2), responsible for the uptake of carnitine into cells. Without functional OCTN2, carnitine cannot be properly absorbed from the diet or conserved by the kidneys, leading to a systemic deficiency.		SPCD is caused by mutations in the [[SLC22A5]] gene, which encodes the organic cation transporter type 2 (OCTN2), responsible for the uptake of carnitine into cells. Without functional OCTN2, carnitine cannot be properly absorbed from the diet or conserved by the kidneys, leading to a systemic deficiency.

	==Symptoms==		==Symptoms==
	Symptoms of SPCD can vary widely among affected individuals but typically include [[muscle weakness]], [[hypoglycemia]] (low blood sugar), [[cardiomyopathy]] (disease of the heart muscle), and [[hepatic encephalopathy]] (brain dysfunction caused by liver disease). Symptoms can appear anytime from infancy to adulthood, with some individuals remaining asymptomatic.		Symptoms of SPCD can vary widely among affected individuals but typically include [[muscle weakness]], [[hypoglycemia]] (low blood sugar), [[cardiomyopathy]] (disease of the heart muscle), and [[hepatic encephalopathy]] (brain dysfunction caused by liver disease). Symptoms can appear anytime from infancy to adulthood, with some individuals remaining asymptomatic.

	==Diagnosis==		==Diagnosis==
	Diagnosis of SPCD involves a combination of clinical evaluation, biochemical tests showing low plasma carnitine levels, and genetic testing confirming mutations in the SLC22A5 gene. Early diagnosis and treatment are crucial to prevent serious complications.		Diagnosis of SPCD involves a combination of clinical evaluation, biochemical tests showing low plasma carnitine levels, and genetic testing confirming mutations in the SLC22A5 gene. Early diagnosis and treatment are crucial to prevent serious complications.

	==Treatment==		==Treatment==
	The primary treatment for SPCD is oral [[L-carnitine]] supplementation, which can significantly improve symptoms and prevent metabolic crises. Patients may also require dietary modifications and management of symptoms related to complications.		The primary treatment for SPCD is oral [[L-carnitine]] supplementation, which can significantly improve symptoms and prevent metabolic crises. Patients may also require dietary modifications and management of symptoms related to complications.

	==Prognosis==		==Prognosis==
	With early diagnosis and appropriate treatment, individuals with SPCD can lead normal, healthy lives. However, untreated SPCD can result in severe metabolic crises, irreversible organ damage, and potentially fatal outcomes.		With early diagnosis and appropriate treatment, individuals with SPCD can lead normal, healthy lives. However, untreated SPCD can result in severe metabolic crises, irreversible organ damage, and potentially fatal outcomes.

	[[Category:Genetic disorders]]		[[Category:Genetic disorders]]
	[[Category:Metabolic disorders]]		[[Category:Metabolic disorders]]
	{{medicine-stub}}		{{medicine-stub}}

Prab: CSV import

2024-04-23T19:44:03Z

CSV import

New page

[[File:Carnitine_structure.png|Carnitine structure|thumb]] '''Systemic Primary Carnitine Deficiency''' (SPCD), also known as '''Carnitine Uptake Defect''' or '''Carnitine Transporter Deficiency''', is a rare [[genetic disorder]] that affects the body's ability to transport [[carnitine]], a substance essential for the oxidation of long-chain [[fatty acids]]. This condition leads to a variety of symptoms, primarily affecting the [[muscle]]s and [[heart]], and can result in serious complications if not treated promptly.

==Causes==
SPCD is caused by mutations in the [[SLC22A5]] gene, which encodes the organic cation transporter type 2 (OCTN2), responsible for the uptake of carnitine into cells. Without functional OCTN2, carnitine cannot be properly absorbed from the diet or conserved by the kidneys, leading to a systemic deficiency.

==Symptoms==
Symptoms of SPCD can vary widely among affected individuals but typically include [[muscle weakness]], [[hypoglycemia]] (low blood sugar), [[cardiomyopathy]] (disease of the heart muscle), and [[hepatic encephalopathy]] (brain dysfunction caused by liver disease). Symptoms can appear anytime from infancy to adulthood, with some individuals remaining asymptomatic.

==Diagnosis==
Diagnosis of SPCD involves a combination of clinical evaluation, biochemical tests showing low plasma carnitine levels, and genetic testing confirming mutations in the SLC22A5 gene. Early diagnosis and treatment are crucial to prevent serious complications.

==Treatment==
The primary treatment for SPCD is oral [[L-carnitine]] supplementation, which can significantly improve symptoms and prevent metabolic crises. Patients may also require dietary modifications and management of symptoms related to complications.

==Prognosis==
With early diagnosis and appropriate treatment, individuals with SPCD can lead normal, healthy lives. However, untreated SPCD can result in severe metabolic crises, irreversible organ damage, and potentially fatal outcomes.

[[Category:Genetic disorders]]
[[Category:Metabolic disorders]]
{{medicine-stub}}

Systemic primary carnitine deficiency - Revision history

Prab: CSV import

Prab: CSV import